{"id":"W2057625697","doi":"10.1517/13543784.2013.831404","title":"Current Phase II clinical data for ridaforolimus in cancer","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"PI3K/AKT/mTOR pathway; mTORC1; mTORC2; Everolimus; Cancer research; Medicine; Cancer; Protein kinase B; Clinical trial; Pharmacology; Signal transduction; Biology; Oncology; Internal medicine; Cell biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001142935,0.000667728,0.001457704,0.0007366913,0.0002233812,0.001018389,0.001147316,0.001069708,0.009466793],"category_scores_gemma":[0.001094514,0.0001859158,0.0007754497,0.0009721191,0.0003667817,0.0008666819,0.0004332956,0.001490557,0.004336516],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005990195,"about_ca_system_score_gemma":0.0009537602,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000543167,"about_ca_topic_score_gemma":0.001291132,"domain_scores_codex":[0.9997467,0.00005992924,0.00003120763,0.00004466792,0.00009115548,0.00002627735],"domain_scores_gemma":[0.999486,0.0001986597,0.0001090823,0.00001642541,0.0001320906,0.00005758951],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003365511,0.0001025709,0.0001801287,0.008781709,0.00009077253,0.000139384,0.00003886618,0.0003396029,0.002424293,0.001464107,0.03326572,0.9528362],"study_design_scores_gemma":[0.00034265,0.0009602517,0.001173046,0.003829787,0.0003040336,0.001629742,0.00004667453,0.0002150033,0.001754179,0.00169256,0.9880266,0.00002552768],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001121187,0.9885911,0.0005675376,0.001541742,0.0004933275,0.00008670321,0.000246482,0.00003729265,0.007314566],"genre_scores_gemma":[0.007308935,0.9841104,0.0008724543,0.002371676,0.0005672573,0.0001412649,0.0005835138,0.00001929666,0.004025262],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.009466793,"threshold_uncertainty_score":0.03166962,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3066120933457857,"score_gpt":0.5347343585449083,"score_spread":0.2281222651991226,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}